Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of 557.93 million. The enterprise value is 780.71 million.
| Market Cap | 557.93M |
| Enterprise Value | 780.71M |
Important Dates
The next estimated earnings date is Friday, May 2, 2025.
| Earnings Date | May 2, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +8.74% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 73.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.04 |
| PB Ratio | 1.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -25.37 |
| EV / Sales | 3.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.89 |
Financial Position
The company has a current ratio of 3.70, with a Debt / Equity ratio of 0.99.
| Current Ratio | 3.70 |
| Quick Ratio | 3.04 |
| Debt / Equity | 0.99 |
| Debt / EBITDA | n/a |
| Debt / FCF | -8.24 |
| Interest Coverage | -8.61 |
Financial Efficiency
Return on equity (ROE) is -7.15% and return on invested capital (ROIC) is -2.99%.
| Return on Equity (ROE) | -7.15% |
| Return on Assets (ROA) | -2.68% |
| Return on Invested Capital (ROIC) | -2.99% |
| Return on Capital Employed (ROCE) | -4.88% |
| Revenue Per Employee | 490,389 |
| Profits Per Employee | -82,279 |
| Employee Count | 374 |
| Asset Turnover | 0.19 |
| Inventory Turnover | 1.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.20% in the last 52 weeks. The beta is 0.38, so Nxera Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -39.20% |
| 50-Day Moving Average | 6.22 |
| 200-Day Moving Average | 7.76 |
| Relative Strength Index (RSI) | 1.82 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of 183.41 million and -30.77 million in losses. Loss per share was -0.34.
| Revenue | 183.41M |
| Gross Profit | 134.96M |
| Operating Income | -42.13M |
| Pretax Income | -29.65M |
| Net Income | -30.77M |
| EBITDA | -16.79M |
| EBIT | -42.13M |
| Loss Per Share | -0.34 |
Balance Sheet
The company has 230.27 million in cash and 431.88 million in debt, giving a net cash position of -201.61 million.
| Cash & Cash Equivalents | 230.27M |
| Total Debt | 431.88M |
| Net Cash | -201.61M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 435.81M |
| Book Value Per Share | 4.85 |
| Working Capital | 268.56M |
Cash Flow
In the last 12 months, operating cash flow was -49.09 million and capital expenditures -3.35 million, giving a free cash flow of -52.44 million.
| Operating Cash Flow | -49.09M |
| Capital Expenditures | -3.35M |
| Free Cash Flow | -52.44M |
| FCF Per Share | n/a |
Margins
Gross margin is 73.59%, with operating and profit margins of -22.97% and -16.78%.
| Gross Margin | 73.59% |
| Operating Margin | -22.97% |
| Pretax Margin | -16.17% |
| Profit Margin | -16.78% |
| EBITDA Margin | -9.16% |
| EBIT Margin | -22.97% |
| FCF Margin | n/a |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.74% |
| Shareholder Yield | -8.74% |
| Earnings Yield | -5.52% |
| FCF Yield | -9.40% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nxera Pharma has an Altman Z-Score of 1.11. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.11 |
| Piotroski F-Score | n/a |